CTIS2024-513316-10-00进行中（未招募）1 期
20200040
Amgen Inc.0 个研究点目标入组 35 人开始时间: 2024年7月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteersdiabetes mellitushypertensionCTIS2024-511526-31-00Celon Pharma S.A.38
进行中（未招募）
1 期
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expressionMedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2023-507486-26-00Bayer Consumer Care AG135
进行中（未招募）
1 期
A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104Prostate cancerCTIS2023-506435-15-00Bayer Consumer Care AG60
招募中
1 期
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid TumorsPatients with Advanced Solid TumorsCTIS2023-506390-35-00Tesaro Inc.840
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulatioInfertility in women undergoing assisted reproductive technologies (ART)CTIS2023-507630-25-00Ferring Pharmaceuticals A/S600